(27%) than older smokers aged 60-69 years (7.2%) . Australian data on daily EC use is not available but is urgently needed to better understand the issue. Some data suggests that 'never smokers' are less likely than 'former or current smokers' to have tried ECs. In 2011-12 'ever users' of ECs among US high school students more than doubled and in 2012, one in five middle school children who identified as 'ever users' of ECs reported never smoking regular cigarettes. 11 Beyond this, a recent study in Ireland showed 5% of smokers began using ECs before they switching to regular cigarettes. 12 Critics have suggested that most of the research that has been undertaken to date is cross sectional and this methodology may not yet have captured the trajectory of uptake of new EC users. 8
Safety of ECs
Although ECs do not deliver tar or carbon monoxide, 13 they do expose users and those nearby to particulate matter, organic compounds and solvents. 14 Many of these chemical substances and particulates are toxic, carcinogenic and cause respiratory and heart distress. 15 In addition, ECs have similar effects as regular cigarettes on the cotinine levels of passive and active smokers. 16 However, due to the relatively short time ECs have been available there is little data relating to t h ei r long-term health effects. A recent systematic review reported that common carcinogens are lower in ECs compared to tobacco products (e.g. nitrosamines). However, the researchers concluded that due to the inconsistencies in evidence and lack of long term results, the safety of ECs cannot be determined at this point in time. 17 Cheng 15 concluded from his systematic review of chemical compositions of EC -juice that the level and type of exposure to users and other people in proximity is difficult to establish. This is due to the range of components in the juices and the differences in delivery performance of EC devices. Although ECs appear to deliver lower levels of some chemicals compared to regular cigarette, there is no evidence that they are a healthier alternative. 18 Drummond warned that the perception of ECs as a harm reduction tool without adequate evidence can be likened to the promotion by tobacco companies of 'light' cigarettes, which were proven not to be safer. 18 
Smoking cessation or marketing tool
The evidence around ECs role in smoking cessation is inconclusive with experts stating 'the goal of ECs makers is not cessation of tobacco use but 'dual use.' 19 The Cochrane review 20 examining ECs as a cessation tool showed that they may have similar efficacy to nicotine patches. However, the findings were inconclusive due to the small amount of evidence available (i.e. only two randomised controlled trials and 11 observational studies).
Promotion of ECs
ECs have increased in popularity and have been enthusiastically promoted as a smoking cessation aid and healthy alternative to regular cigarettes, even though these claims are unsubstantiated. 21 Major tobacco companies are purchasing or developing EC products, 7 and using websites and twitter to reach large audiences at a relatively cheap cost. 22 At the 2014 Electronic Cigarette Education Summit, a Wells Fargo Securities Senior Analyst projected that EC consumption could surpass regular cigarettes in 10 years. 23 Grana and colleagues 7 reviewed 59 websites that sold ECs and found claims such as, ECs were a healthier product (95%), cheaper and cleaner than regular cigarettes (93%), can be smoked anywhere (88%), used to get around smoke-free polices (71%), no side-stream smoke just water vapour (76%) and could act as a worthwhile cessation aid (64%). These marketing messages are also repeated via social media such as Facebook and twitter, where EC companies have a strong presence. This is the perfect place to reach new markets as Twitter users are mainly from younger age groups. 24 In addition, some ECs are promoted as a lifestyle choice, associated with stylish accessories and celebrities. They 
Regulation of sales of ECs
Many countries have banned over the counter sales of ECs including Australia, Canada, Mexico, and Brazil. As a consequence, ECs are sold largely via the internet, making their sales difficult to regulate but still accessible, particularly to the young, as this is their preferred purchasing medium. 26 In early 2014 there was an estimated 466 brands of ECs available on line, with up to 50% of sales occurring on the internet. 27 The exact amount of sales of ECs is difficult to determine, although two US companies reported selling 735,000 ECs in a year. 13 Australian laws covering ECs are complex, vary between states and are difficult to enforce. 10 Currently, tobacco control laws do not apply to ECs, rather poisons control legislation in all Australian jurisdictions prevents the sale, possession or use of non-therapeutic nicotine without a licence. A few states (e.g. Western Australia, South Australia and Queensland) have also banned delivery devices that do not contain nicotine but resemble tobacco products, products which may be particularly attractive to children. 28 In Australia the regulation for the importation of ECs by purchasers is detailed on the Customs Website (http://www.customs.gov.au/faq/AlcoholCigTobacco2.asp#Q365), with EC regulations relating to EC importation appearing quite convoluted. The information on the site states that in Australia liquid nicotine is listed as a 'Schedule 7 Poison' under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) but it is not a prohibited import. They may be subject to control under the Therapeutic Goods (TGA) Act 1989 if the packaging makes a claim about any form of therapeutic benefit but this is not usually included on the packaging. If no therapeutic claim is made, or the TGA determines that no action is warranted, the goods are released to the purchaser. These products are not deemed to be tobacco or tobacco products, and therefore are not subject to duty or GST if the customs value is at or below the low value goods threshold of A$1,000. 29 This makes the purchase of ECs via the internet, appealing and relatively easy.
Restricting use of ECs
The WHO has called for greater restrictions on the use, sale and promotion of ECs as there is limited evidence on their safety and their role to help smokers to quit. 30 The Cancer Council, Australia and National Heart Foundation support a ban on the sale of nicotine delivery devices. 31 A recent position statement by the NHMRC reported that there is insufficient evidence that ECs are a safe alternative to tobacco and supports research to assess their health impact 32 
and the Australian Medical Association
is concerned about the increasing use of ECs, calling for tougher regulations. 33 A number of cities in the US have moved to address the use of ECs. The city of Boston has applied workplace EC bans, with New York and Los Angeles ready to introduce legislation that will prohibit their use in public places. 19 In Australia, the University of South Australia lead the charge, announcing on May 31 2014 34 that they would ban the use of ECs on campus. This has been followed by the Australian National University whose ban on ECs became effective on May 31 2015. 35 Queensland is the first Australian state to subject ECs to the same laws for people who use regular cigarettes with amendments to the Tobacco Control Act taking effect in January 2015. 36 
Implications for Health Promotion
The health promotion community is in an unenviable situation with limited data on which to base their position on ECs. Hence, there is no firm consensus. Some see ECs as a safe form of nicotine delivery in comparison to regular tobacco, as well as a tobacco cessation device and harm reduction strategy, even though they have not been adequately tested, standardised or regulated. 37 Others see it as a coercive entry point or 'gateway' for the young to a life of smoking and ill health, and an ideal opportunity for the re-normalising and re-glamourizing of societal smoking. 38 However, we should remember that nicotine replacement and cessation programs played only a minor role in the decline in regular smoking prevalence. The main influences were due to a comprehensive health promotion approach of that restricted access and opportunities to smoke. It appears that we will have to remain wary of the tobacco industry as their recent actions mirror a history of deviousness. 1 This was illustrated in New South Wales recently, where the state government delayed laws to restrict minors from obtaining ECs after Members of Parliament were approached by lobbyists representing multinational tobacco companies. 39 This ongoing distrust of the tobacco industry provides good reason for their exclusion from any policy development related to ECs.
From the limited evidence we have to date on ECs, it is apparent that a cautious approach is warranted with a case that supports strict regulation until rigorous research is conducted. The same rigor that is applied to new therapeutic products needs to be applied to ECs. Randomised controlled trials are needed to compare ECs to other nicotine replacement therapies and research studies should be designed to assess long-term health outcomes of EC use.
Legislation should be considered that restricts EC sales to adults over 18 years who are attempting to reduce or quit smoking. This could be an interim measure based on the assumption that research may eventually indicate relative safety as well as effectiveness of ECs as a cessation agent. Legislation should also consider: standardisation of EC products; a requirement that all EC brands list their juice ingredients and nicotine contents; restrictions on the flavours to make them less appealing to children; making juice containers childproof; non-glamorised common generic packaging; careful controls on the marketing of ECs; restricting sales avenues, banning of online sales/purchases; and banning of unsubstantiated claims regarding quitting and health benefits.
In conclusion, there are still too many unknowns about the likely consequences of EC use to allow it uncontrolled availability and we therefore need to consider the 'precautionary principle' when dealing with this issue. Short-term research should be able to identify the relative safety of the product and its benefits as a cessation agent. However, long-term research may be necessary to identify its potential impact on smoking behaviours of children, youth and adults, including rates of uptake. As ECs are a smoking related product with close connections to the tobacco industry, 'caution is the better part of valour'! We do not want decades of health promotion practice and public health policy that has successfully reduced smoking prevalence to be undone. 
